anti-HER2-ATAC (Heidelberg Pharma)

N/A

Report date: 2025/03/14 16:35:21

Base Information

Drug Nameanti-HER2-ATAC (Heidelberg Pharma)

Drug Alias Nameamanitin-HER2 antibody drug conjugate (Heidelberg Pharma)anti-HER2-THIOMAB-ATACanti-HER2-antibody targeted amanitin conjugates (Heidelberg Pharma)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHeidelberg Pharma AG

China Registration ClassN/A

Develop Information

Active CompaniesHeidelberg Pharma AG

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A